Antisense Therapeutics Limited (ANP.AX) Release: ATL1102 for Multiple Sclerosis -Toxicology Study to Commence
5/2/2013 1:42:18 PM
More...
|
Antisense Therapeutics Limited (ANP.AX) and TJAB Advance MS Drug
3/19/2013 2:45:04 PM
More...
|
Antisense Therapeutics Limited (ANP.AX) Announces ATL1103 on Track to Move Into Clinical Development
10/13/2009 10:18:13 AM
More...
|
Antisense Therapeutics Limited (ANP.AX) to Present at Rodman & Renshaw 11th Annual Healthcare Conference
8/31/2009 10:15:12 AM
More...
|
Antisense Therapeutics Limited (ANP.AX) Drug ATL1101 Enhances Effect of Existing Chemotherapy Treatment on Prostate Tumors
6/18/2009 10:13:33 AM
More...
|
Antisense Therapeutics Limited (ANP.AX) to Present at Rodman & Renshaw 10th Annual Healthcare Conference
10/27/2008 10:00:31 AM
More...
|
Isis Pharmaceuticals, Inc. (ISIS), Antisense Therapeutics Limited (ANP.AX) ATL/TV1102 Trial Results Presented at World Congress on Treatment and Research in Multiple Sclerosis
9/22/2008 11:28:03 AM
More...
|
Teva Pharmaceutical Industries Limited (TEVA) & Antisense Therapeutics Limited (ANP.AX) Announce That ATL/TV1102, a Novel Drug for the Treatment of Relapsing Remitting Multiple Sclerosis (RRMS), Demonstrated Significant Reduction in Disease Activity
6/30/2008 10:05:01 AM
More...
|
Antisense Therapeutics Limited (ANP.AX) to Present at Sachs Associates 7th Annual North America Forum for Investing and Partnering in Biotech
2/22/2008 9:42:14 AM
More...
|
Antisense Therapeutics Limited (ANP.AX) Licenses ATL1102 to Teva Pharmaceutical Industries Limited (TEVA)
2/20/2008 8:50:26 AM
More...
|
|